share_log

藥明生物：截至2024年4月30日止股份發行人的證券變動月報表

WUXI BIO: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2024

Hong Kong Stock Exchange ·  May 6 16:32
Summary by Futu AI
藥明生物（WuXi Biologics (Cayman) Inc.）於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的公司股份變動情況。報告顯示，公司的法定/註冊股本維持不變，總數為6,000,000,000股，每股面值為USD1/120,000，法定/註冊股本總額為50,000美元。此外，報告亦涵蓋了股份期權計劃的變動，包括首次公開發售前購股權計劃的行使情況，以及受限制股份獎勵計劃和全球合夥人計劃的股份獎勵計劃。在報告期間，公司通過股份期權計劃行使了期權，獲得資金總額為414,331.86美元。同時，公司於2023年6月27日至2024年4月30日期間購回了合共96,611,000股普通股，但這些股份於報告截止日期尚未註銷。藥明生物確認，所有發行的證券均已獲董事會正式授權批准，並符合相關上市規則的要求。
藥明生物（WuXi Biologics (Cayman) Inc.）於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的公司股份變動情況。報告顯示，公司的法定/註冊股本維持不變，總數為6,000,000,000股，每股面值為USD1/120,000，法定/註冊股本總額為50,000美元。此外，報告亦涵蓋了股份期權計劃的變動，包括首次公開發售前購股權計劃的行使情況，以及受限制股份獎勵計劃和全球合夥人計劃的股份獎勵計劃。在報告期間，公司通過股份期權計劃行使了期權，獲得資金總額為414,331.86美元。同時，公司於2023年6月27日至2024年4月30日期間購回了合共96,611,000股普通股，但這些股份於報告截止日期尚未註銷。藥明生物確認，所有發行的證券均已獲董事會正式授權批准，並符合相關上市規則的要求。
WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) filed with Hong Kong Trading and Clearing Limited on May 6, 2024 its latest Securities Changes Monthly Report, reporting the changes in the company's shares for the year ended April 30, 2024. The report showed that the company's regulated/registered share capital remained unchanged with a total of 6,000,000,000 shares, a face value of USD1/120,000 per share, and a total regulated/registered share capital of $50,000. In addition, the report also covers changes in share option schemes, including the performance of the Initial Public Offering pre-IPO share option scheme and share award schemes under the Restricted Share Award Scheme and Global Partner Scheme. During the reporting period, the company exercised options through the stock option program...Show More
WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) filed with Hong Kong Trading and Clearing Limited on May 6, 2024 its latest Securities Changes Monthly Report, reporting the changes in the company's shares for the year ended April 30, 2024. The report showed that the company's regulated/registered share capital remained unchanged with a total of 6,000,000,000 shares, a face value of USD1/120,000 per share, and a total regulated/registered share capital of $50,000. In addition, the report also covers changes in share option schemes, including the performance of the Initial Public Offering pre-IPO share option scheme and share award schemes under the Restricted Share Award Scheme and Global Partner Scheme. During the reporting period, the company exercised options through the stock option program, which received a total of $414,331.86 in funds. At the same time, the Company repurchased a total of 96,611,000 shares of ordinary shares between June 27, 2023 and April 30, 2024, but these shares have not been written off at the reporting deadline. Pharma Biologics confirms that all securities issued have been formally authorized by the Board of Directors and comply with the requirements of the relevant Listing Rules.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.